BSFAF
Price
$0.04
Change
-$0.02 (-33.33%)
Updated
May 14 closing price
Capitalization
3.94M
CERO
Price
$0.45
Change
-$0.07 (-13.46%)
Updated
May 30 closing price
Capitalization
3.43M
Interact to see
Advertisement

BSFAF vs CERO

Header iconBSFAF vs CERO Comparison
Open Charts BSFAF vs CEROBanner chart's image
BSF Enterprise
Price$0.04
Change-$0.02 (-33.33%)
Volume$10K
Capitalization3.94M
CERo Therapeutics Holdings
Price$0.45
Change-$0.07 (-13.46%)
Volume$4.03M
Capitalization3.43M
BSFAF vs CERO Comparison Chart
Loading...
CERO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BSFAF vs. CERO commentary
Jun 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSFAF is a Buy and CERO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 01, 2025
Stock price -- (BSFAF: $0.04 vs. CERO: $0.45)
Brand notoriety: BSFAF and CERO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BSFAF: 124% vs. CERO: 164%
Market capitalization -- BSFAF: $3.94M vs. CERO: $3.43M
BSFAF [@Biotechnology] is valued at $3.94M. CERO’s [@Biotechnology] market capitalization is $3.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $303.58B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BSFAF’s FA Score shows that 1 FA rating(s) are green whileCERO’s FA Score has 1 green FA rating(s).

  • BSFAF’s FA Score: 1 green, 4 red.
  • CERO’s FA Score: 1 green, 4 red.
According to our system of comparison, BSFAF is a better buy in the long-term than CERO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERO’s TA Score shows that 4 TA indicator(s) are bullish.

  • CERO’s TA Score: 4 bullish, 4 bearish.

Price Growth

BSFAF (@Biotechnology) experienced а 0.00% price change this week, while CERO (@Biotechnology) price change was -15.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.39%. For the same industry, the average monthly price growth was +0.48%, and the average quarterly price growth was -5.03%.

Reported Earning Dates

CERO is expected to report earnings on Apr 15, 2025.

Industries' Descriptions

@Biotechnology (+1.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BSFAF($3.94M) has a higher market cap than CERO($3.43M). BSFAF YTD gains are higher at: -12.500 vs. CERO (-92.577). BSFAF has higher annual earnings (EBITDA): -1.68M vs. CERO (-9.78M). CERO has more cash in the bank: 3.38M vs. BSFAF (1.37M). BSFAF has less debt than CERO: BSFAF (118K) vs CERO (1.81M). BSFAF has higher revenues than CERO: BSFAF (67.2K) vs CERO (0).
BSFAFCEROBSFAF / CERO
Capitalization3.94M3.43M115%
EBITDA-1.68M-9.78M17%
Gain YTD-12.500-92.57714%
P/E RatioN/AN/A-
Revenue67.2K0-
Total Cash1.37M3.38M41%
Total Debt118K1.81M7%
TECHNICAL ANALYSIS
Technical Analysis
CERO
RSI
ODDS (%)
Bullish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
59%
Momentum
ODDS (%)
Bearish Trend 3 days ago
35%
MACD
ODDS (%)
Bearish Trend 3 days ago
23%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
62%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
76%
Advances
ODDS (%)
Bullish Trend 14 days ago
52%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
63%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CERO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCBAX15.000.03
+0.20%
BlackRock Tactical Opportunities Inv A
FSPGX39.07-0.01
-0.03%
Fidelity Large Cap Growth Idx
LSVGX15.13-0.02
-0.13%
LSV Global Value Institutional
SMDIX18.80-0.07
-0.37%
Hartford Schroders US MidCap Opps I
IVVIX18.78-0.07
-0.37%
Macquarie Smid Cap Core Fund Class I

BSFAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, BSFAF has been closely correlated with BIESF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSFAF jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BSFAF
1D Price
Change %
BSFAF100%
N/A
BIESF - BSFAF
82%
Closely correlated
N/A
SOLTF - BSFAF
29%
Poorly correlated
N/A
YECO - BSFAF
24%
Poorly correlated
N/A
APLM - BSFAF
21%
Poorly correlated
-1.93%
CERO - BSFAF
21%
Poorly correlated
-13.85%
More

CERO and

Correlation & Price change

A.I.dvisor tells us that CERO and BRTX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CERO and BRTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERO
1D Price
Change %
CERO100%
-13.85%
BRTX - CERO
30%
Poorly correlated
+0.29%
KRON - CERO
27%
Poorly correlated
+0.52%
GOVX - CERO
26%
Poorly correlated
-4.67%
AGEN - CERO
25%
Poorly correlated
+7.19%
ANTX - CERO
24%
Poorly correlated
-12.40%
More